Table 1.
Summary statistics for the meta-analysis split into each cohort
| Variable | Overall | DeKAF | FRCBS | GEN03 | KiT-GENIE | QUB | TL | UKIRTC |
|---|---|---|---|---|---|---|---|---|
| Number of patients | 6,666 | 684 | 929 | 476 | 1853 | 133 | 696 | 1895 |
| Donor age, median (min–max) | 50 (18–90) | 44 (18–70) | 58 (18–77) | 45 (18–71) | 55 (18–90) | 40 (18–68) | 46 (18–72) | 47 (18–81) |
| Female donor, n (%) | 3106 (47) | 405 (59) | 433 (47) | 273 (57) | 776 (42) | 58 (44) | 344 (49) | 817 (43) |
| Donor type | ||||||||
| Living, n (%) | 1582 (24) | 684 (100) | 0 (0) | 476 (100) | 319 (17) | 0 (0) | 103 (15) | 0 (0) |
| Other COD, n (%) | 1971 (30) | 0 (0) | 311 (33) | 0 (0%) | 655 (35) | 55 (41) | 249 (36) | 701 (37) |
| Stroke COD, n (%) | 3113 (47) | 0 (0) | 618 (67) | 0 (0) | 879 (47) | 78 (59) | 344 (49) | 1194 (63) |
| Recipient age, median (min–max) | 51 (0–84) | 51 (0–83) | 57 (18–79) | 51 (1–81) | 53 (18–84) | 43 (4–72) | 49 (15–74) | 47 (18–79) |
| Female recipient, n (%) | 2391 (36) | 231 (34) | 290 (31) | 177 (37) | 657 (35) | 56 (42) | 282 (41) | 698 (37) |
| Year of transplant, median (min–max) | 2007 (1981–2020) | 2008 (2006–2010) | 2014 (2007–2017) | 2014 (2012–2015) | 2011 (1999–2020) | 1997 (1986–2005) | 2000 (1993–2008) | 2001 (1981–2007) |
| PRD | ||||||||
| Glomerulonephritis | 772 (12) | 175 (26) | 125 (13) | 162 (34) | 0 (0) | 9 (7) | 139 (20) | 162 (9) |
| IgA nephropathy | 313 (5) | 0 (0) | 119 (13) | 0 (0) | 0 (0) | 10 (8) | 49 (7) | 135 (7) |
| Other | 3283 (49) | 198 (29) | 293 (32) | 122 (26) | 1569 (85) | 74 (56) | 311 (45) | 716 (38) |
| PKD | 990 (15) | 107 (16) | 191 (21) | 76 (16) | 284 (15) | 20 (15) | 89 (13) | 223 (12) |
| Type 2 diabetes | 366 (6) | 175 (26) | 76 (8) | 86 (18) | 0 (0) | 4 (3.) | 5 (1) | 20 (1) |
| Unknown | 942 (14) | 29 (4.2) | 125 (13) | 30 (6) | 0 (0) | 16 (12) | 103 (15) | 639 (34) |
| First transplant, n (%) | 5852 (88) | 603 (88) | 929 (100) | 420 (88) | 1450 (78) | 133 (100) | 637 (92) | 1680 (89) |
| Follow up, median (min–max) | 5 (0–25) | 2 (0.4–5) | 3 (0–10) | 2 (0.4–3) | 6 (0–21) | 8 (0–25) | 7 (0–17) | 8 (0–25) |
| Graft status, n (%) | ||||||||
| Censored | 5577 (84) | 671 (98) | 871 (94) | 474 (99.6) | 1439 (78) | 92 (69) | 586 (84) | 1444 (76) |
| Rejected | 1089 (16) | 13 (2) | 58 (6) | 2 (0.4) | 414 (22) | 41 (31) | 110 (16) | 451 (24) |
| eGFR at 1 year, median (min–max) | 53 (4–185) | 60 (4–178) | 54 (6–135) | 62 (16–185) | 51 (8–129) | NA | 47 (4–124) | 50 (6–124) |
| Unknown, n (%) | 1030 (15) | 0 (0) | 269 (29) | 0 (0) | 168 (9) | 133 (100) | 59 (8) | 401 (21) |
| eGFR at 5 years, median (min–max) | 49 (3–124) | NA | 50 (13–106) | NA | 50 (7–122) | NA | 50 (3–124) | 48 (6–121) |
| Unknown | 3865 | 684 | 829 | 476 | 839 | 133 | 215 | 689 |
Descriptive characteristics for the following cohorts: eGFR is in units of mL/min/1.73 m2. First transplant refers to whether it is the recipient’s first transplant or not. The numbers in each cohort refer to the number of donor kidneys rather than just the number of donors, as one deceased donor may donate two kidneys. Follow up is the mean death-censored graft survival time. Further information on each cohort can be found in Supplementary Materials description of datasets
DeKAF Deterioration of kidney allograft function, FRCBS Finnish red cross blood service, KiT-GENIE kidney transplantation-genomic investigation of essential clinical concerns, TL transplant lines, QUB Queen’s University Belfast, UKIRTC United Kingdom and Ireland Renal Transplant consortium. PRD primary renal disease at transplant, COD cause of death, PKD polycystic kidney disease